{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:12:46Z","timestamp":1792501966592,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.amjcard.2020.08.049","type":"journal-article","created":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T22:04:30Z","timestamp":1600121070000},"page":"32-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Usefulness of Lipoprotein (a) for Predicting Outcomes After Percutaneous Coronary Intervention for Stable Angina Pectoris in Patients on Hemodialysis"],"prefix":"10.1016","volume":"136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4098-8231","authenticated-orcid":false,"given":"Keiichi","family":"Hishikari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Hikita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiyuki","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihoko","family":"Tsujihata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naruhiko","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Kanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munehiro","family":"IIya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Murai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1798-5008","authenticated-orcid":false,"given":"Taishi","family":"Yonetsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3582-6104","authenticated-orcid":false,"given":"Tetsuo","family":"Sasano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2020.08.049_bib0001","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1053\/ajkd.1998.v32.pm9820470","article-title":"Clinical epidemiology of cardiovascular disease in chronic renal disease","volume":"32","author":"Foley","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.amjcard.2020.08.049_bib0002","first-page":"S1","article-title":"Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to know? Where do we go from here?","volume":"32","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.amjcard.2020.08.049_bib0003","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","article-title":"Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention","volume":"108","author":"Sarnak","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2020.08.049_bib0004","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1681\/ASN.V61110","article-title":"Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypesinpatientswithend-stagerenaldiseasetreated by hemodialysis or continuous ambulatory peritoneal dialysis","volume":"6","author":"Kronenberg","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjcard.2020.08.049_bib0005","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.ATV.10.5.672","article-title":"Lipoprotein(a): A unique risk factor for atherothrombotic disease","volume":"10","author":"Loscalzo","year":"1990","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.amjcard.2020.08.049_bib0006","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1073\/pnas.84.10.3224","article-title":"Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen","volume":"84","author":"Eaton","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.amjcard.2020.08.049_bib0007","first-page":"249","article-title":"Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction","volume":"62","author":"Murai","year":"1986","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2020.08.049_bib0008","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/1526602817728068","article-title":"Usefulness of lipoprotein(a) for predicting clinical outcomes after endovascular therapy for aortoiliac atherosclerotic lesions","volume":"24","author":"Hishikari","year":"2017","journal-title":"J Endovasc Ther"},{"key":"10.1016\/j.amjcard.2020.08.049_bib0009","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0021-9150(86)90099-7","article-title":"The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis: dependence on serum LDL levels","volume":"62","author":"Armstrong","year":"1986","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2020.08.049_bib0010","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0021-9150(74)90016-1","article-title":"A study of methods of identification and estimation of Lp(a) lipoprotein and of its significance in health, hyperlipidaemia and atherosclerosis","volume":"20","author":"Walton","year":"1974","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2020.08.049_bib0011","first-page":"2506","article-title":"Third universal definition of myocardial infarction","volume":"33","author":"Taylor","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2020.08.049_bib0012","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1253\/circj.CJ-11-0365","article-title":"Usefulness of lipoprotein (a) for predicting progression of non-culprit coronary lesions after acute myocardial infarction","volume":"75","author":"Ikenaga","year":"2011","journal-title":"Circ J"},{"key":"10.1016\/j.amjcard.2020.08.049_bib0013","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.amjcard.2016.08.067","article-title":"Impact of lipoprotein(a) on long-term outcomes in patients with diabetes mellitus who underwent percutaneous coronary intervention","volume":"118","author":"Konishi","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2020.08.049_bib0014","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ijcard.2015.12.007","article-title":"Plasma lipoprotein(a) predicts major cardiovascular events in patients with chronic kidney disease who undergo percutaneous coronary intervention","volume":"205","author":"Konishi","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2020.08.049_bib0015","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1016\/j.amjcard.2018.04.058","article-title":"Association of plasma lipoprotein(a) with long-term adverse events in patients with chronic kidney disease who underwent percutaneous coronary intervention","volume":"122","author":"Xu","year":"2018","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2020.08.049_bib0016","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1172\/JCI117598","article-title":"The role of lecithin: cholesterol acyltransferase for lipoprotein (a) assembly. Structural integrity of low density lipoproteins is a prerequisite for Lp(a) formation in human plasma","volume":"94","author":"Steyrer","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjcard.2020.08.049_bib0017","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1253\/circj.CJ-11-0365","article-title":"Usefulness of lipoprotein (a) for predicting progression of non-culprit coronary lesions after acute myocardial infarction","volume":"75","author":"Ikenaga","year":"2011","journal-title":"Circ J"},{"key":"10.1016\/j.amjcard.2020.08.049_bib0018","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1161\/ATVBAHA.113.302479","article-title":"Plasma lipoprotein(a) concentration predicts coronary and cardiovascular events in patients with stable coronary heart disease","volume":"33","author":"Nestel","year":"2013","journal-title":"Atheroscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjcard.2020.08.049_bib0019","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1161\/01.CIR.86.2.475","article-title":"Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients","volume":"86","author":"Cressman","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2020.08.049_bib0020","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1681\/ASN.2004110922","article-title":"High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients","volume":"16","author":"Longenecker","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjcard.2020.08.049_bib0021","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/clinchem\/33.5.721","article-title":"Lp(a) lipoprotein in patients with chronic renal failure treated by hemodialysis","volume":"33","author":"Parra","year":"1987","journal-title":"Clin Chem"},{"key":"10.1016\/j.amjcard.2020.08.049_bib0022","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3109\/0886022X.2010.486097","article-title":"Lipoprotein-A and carotid intima media thickness as cardiovascular risk factors in patients of chronic kidney disease","volume":"32","author":"Aggarwal","year":"2010","journal-title":"Ren Fail"},{"key":"10.1016\/j.amjcard.2020.08.049_bib0023","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.jacc.2012.04.038","article-title":"Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies","volume":"60","author":"Tsimikas","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2020.08.049_bib0024","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.phrs.2017.02.001","article-title":"Lipoprotein(a) and inflammation: a dangerous duet leading to endothelial loss of integrity","volume":"119","author":"Pirro","year":"2017","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.amjcard.2020.08.049_bib0025","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1194\/jlr.R060582","article-title":"Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?","volume":"57","author":"Boffa","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.amjcard.2020.08.049_bib0026","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1126\/science.8503012","article-title":"Proliferation of human smooth muscle cells promoted by lipoprotein(a)","volume":"260","author":"Grainger","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.amjcard.2020.08.049_bib0027","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.116.025253","article-title":"Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans","volume":"135","author":"Reyes-Soffer","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2020.08.049_bib0028","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1093\/eurheartj\/ehy122","article-title":"Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics","volume":"39","author":"Watts","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2020.08.049_bib0029","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1194\/jlr.P082834","article-title":"Effects of mipomersen, an apolipoprotein B100 antisense, on lipoprotein (a) metabolism in healthy subjects","volume":"59","author":"Nandakumar","year":"2018","journal-title":"J Lipid Res"},{"key":"10.1016\/j.amjcard.2020.08.049_bib0030","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.amjcard.2014.05.060","article-title":"Effect of alirocumab, a monoclonal proprotein convertase subtilisin\/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials)","volume":"114","author":"Ginsberg","year":"2014","journal-title":"Am J Cardiol"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914920309498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914920309498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:35:27Z","timestamp":1757572527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914920309498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":30,"alternative-id":["S0002914920309498"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2020.08.049","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Usefulness of Lipoprotein (a) for Predicting Outcomes After Percutaneous Coronary Intervention for Stable Angina Pectoris in Patients on Hemodialysis","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2020.08.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}